Clinical Updates on the Treatment of Advanced Cholangiocarcinoma

Dr Sameek Roychowdhury, of the James Cancer Hospital Solove Research Institute, describes what cholangiocarcinoma is, specifically highlighting how the disease often presents in patients.

GI oncologists explain the complicated nature of cholangiocarcinoma as it relates to the disease’s underlying pathogenesis.

Factors that may contribute to the rise in the number of cholangiocarcinoma cases being reported, as suggested by GI oncologists.

Types of assessments that are used to help appropriately work up a patient suspected of having a bile duct cancer.

Best practices for working with other colleagues to ensure adequate tissue collection occurs when conducting a biopsy on a patient suspected of having cholangiocarcinoma, as well as considerations for next-generation sequencing.

GI oncologists react to a prognosis for patients with newly diagnosed advanced cholangiocarcinoma and discuss how they counsel patients on goals of care and treatment expectations.

Panelists discuss types of scans and other testing results that can be used to help identify patients with an advanced bile duct cancer who are eligible for surgical resection.

Scenarios for which liver transplantation may be appropriate in advanced cholangiocarcinoma.

Current treatment approaches for advanced cholangiocarcinoma, despite current gaps that can be considered in the adjuvant setting, as highlighted by GI oncologists.

Insight regarding best timing to initiate an appropriate adjuvant therapy in patients with advanced cholangiocarcinoma, and the role of ctDNA analysis in the postsurgical setting.

An overview of potential options, as well as trials, further exploring neoadjuvant approaches for the management of patients with advanced cholangiocarcinoma.

Treatment recommendations, including supportive care options and the role of liver-directed therapy for patients with an unresectable, advanced bile duct cancer.

A panel of GI oncologists comment on the transition to targeted therapy and immunotherapy as treatments for advanced cholangiocarcinoma, as well as highlight predictive and prognostic markers that can help guide treatment decisions with novel therapies.

Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing. 

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.

An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.

The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.